Evotec stock under pressure as guidance cut and five-year low weigh on sentiment

Evotec SE (ISIN DE0005664809) stock is trading close to multi-year lows as of August 31, 2026, after the Hamburg-based drug discovery and development company cut its full-year 2026 EBITDA guidance into negative territory and reported weak mid-year figures.

Guidance cut drives renewed downside

Per a September 1, 2026 report, Evotec has lowered its guidance for adjusted group EBITDA for fiscal 2026 to a range between minus EUR 70 million and minus EUR 105 million, signaling that the company now expects a substantial operating loss for the year rather than a profit. The guidance update discussion describes this reduction as a renewed and pronounced cut compared with previous expectations.

The same coverage notes that the guidance revision was communicated together with Evotec's latest half-year results, implying that the company used its mid-2026 reporting window to reset expectations for profitability. While the exact prior guidance range is not stated in that summary, the move from a previously positive or less negative outlook to a clearly negative adjusted EBITDA band represents a material deterioration in the profit outlook for 2026.

For investors, the negative EBITDA guidance matters because it indicates that Evotec will be consuming cash in its operations over the course of fiscal 2026 rather than generating it, placing more weight on its balance sheet strength and on future milestone and royalty inflows from partnered projects.

Shares trade close to 52-week and five-year lows

The guidance cut has coincided with pronounced share price weakness. According to the September 1, 2026 commentary on the mid-year figures and guidance change, Evotec shares recently traded at EUR 3.28, with the stock described as being only 2.7 percent above its 52-week low, underscoring how the equity market has repriced the company lower over the past twelve months. The same guidance-focused article highlights that since the start of 2026 Evotec's share price decline has totaled 40 percent, giving a clear year-to-date performance metric relative to the segment.

Separate market data from late trading on August 31, 2026 show Evotec AG O.N. (ticker EVTG on the Frankfurt Stock Exchange) finishing the session at EUR 3.25, down 3.05 percent on the day, and touching a five-year low in the process. A Germany equity market recap notes that Evotec's decline of 3.05 percent or EUR 0.10 to EUR 3.25 left the stock at a five-year low by the close.

A separate intraday snapshot on August 31, 2026 mentions the share trading around EUR 3.2580 with a daily loss of 3.04 percent, reinforcing that the stock continues to weaken within a narrow band around its recent lows rather than rebounding. The commentary on share weakness characterizes Evotec's performance as fragile in this price zone.

On the US market, Evotec's Nasdaq-listed security, which trades under a separate ticker, has also shown pronounced downside. One August 31, 2026 alert states that this share reached a new 52-week low of $1.86 intraday, below the previous close of $1.91, with the price trading under both its 50-day and 200-day moving averages. The Nasdaq-focused alert underscores that investors in the US-listed line have experienced similar technical pressure and that the stock remains in a clear downtrend.

The comparison between the European quote at EUR 3.25 and the US quote at $1.86, taken together with the 2.7 percent distance to the 52-week low and the stated five-year low, shows that Evotec's equity valuation is currently anchored at the bottom of its recent trading ranges across venues.

Recent fundamentals and mid-year context

The fresh guidance and share price data sit against the backdrop of Evotec's mid-2026 operating performance. While the available summaries focus more on the guidance reduction than on the detailed income statement or revenue breakdown, the use of adjusted group EBITDA as the main guidance metric indicates that Evotec continues to be evaluated by investors on its operating profitability and cash flow rather than on net income alone.

At mid-year 2026, the company has evidently determined that the trajectory of its operating expenses and revenue streams from discovery alliances, clinical programs, and service contracts will result in a negative adjusted EBITDA range for the full year. The announced range from minus EUR 70 million to minus EUR 105 million sets a bandwidth for the expected operating loss before non-recurring items, making it possible to compare eventual reported results with this guidance once fiscal 2026 closes.

Historically, Evotec has reported positive adjusted EBITDA in earlier years when its pipeline milestones and partnered projects delivered stronger inflows relative to its fixed cost base. The shift to a negative range in fiscal 2026 therefore marks a significant change in the near-term financial profile, even though the company's long-term value is still tied to its partnered and proprietary drug discovery programs.

In addition, the statement that Evotec's shares have lost 40 percent since the start of 2026 provides a clear comparison for investors against broad European indices and biotech peers. While the DAX index declined 1.09 percent on August 31, 2026, according to the same Germany equity market overview that highlighted Evotec as the worst performer of the session, the magnitude of Evotec's year-to-date drop is much larger than the modest index move, underlining that the pressure is company-specific rather than purely macro-driven.

Product and business model: partnered drug discovery

Evotec's core business model centers on partnered drug discovery and development, combining high-throughput screening, medicinal chemistry, biology, and clinical capabilities to advance compounds for large pharmaceutical and biotech partners. The company typically earns revenues from research payments, milestones, and potential royalties on successfully commercialized therapies, while also running selected proprietary programs in areas such as neurology, oncology, and metabolic diseases.

In practical terms, Evotec's technology platforms aim to improve the efficiency and success rate of early-stage drug discovery by integrating omics data, computational tools, and laboratory automation. This partnership-heavy model spreads development risk but also means that near-term profitability can be sensitive to the timing of contract signings, milestone achievements, and partner decisions on advancing or discontinuing programs.

For retail investors, the current guidance cut and share price weakness do not change the basic structure of Evotec's business model, but they highlight that the company is willing to spend heavily on R&D and platform investments in 2026 even at the cost of negative adjusted EBITDA, hoping that future partnered successes will ultimately justify the near-term financial impact.

Latest trading context for Evotec stock

Based on the quoted German market data, Evotec AG O.N. trades on the Frankfurt Stock Exchange under the ticker EVTG, with the share price at EUR 3.25 as of the close on August 31, 2026 in late trade. The Germany stock market wrap describes Evotec as the weakest name in its segment on that day, down 3.05 percent.

On the Nasdaq line, the intraday low of $1.86 on August 31, 2026 compared with the previous close of $1.91 and technical levels such as the 50-day and 200-day moving averages, both of which the stock trades below. The technical-focused alert uses this configuration to frame the move as a clear continuation of the downtrend rather than a short-lived dip.

While detailed intraday volume figures and market capitalization are not specified in the accessible summaries, the combination of a five-year low, a 52-week low zone, and a 40 percent year-to-date decline provides several quantitative markers of where Evotec stock now stands. In particular, the fact that the share is only 2.7 percent above its 52-week low at EUR 3.28, as stated on September 1, 2026, shows that recent selling has pushed the price very close to its lowest level of the past twelve months, leaving relatively little buffer before a fresh low would be set if new negative news emerged.

Given the updated guidance and the technical picture, many investors may now focus on whether Evotec can stabilize its operating performance over the remainder of fiscal 2026, deliver contract wins, or see partner programs advance to milestones that could improve profitability and help the share price recover from current depressed levels.

Read more

Further information on Evotec's investor relations activities, including past reports and corporate presentations, can be accessed on the company's official website via its investor relations section.

Representative platform: integrated drug discovery services

A representative aspect of Evotec's offering is its integrated discovery services platform, which packages target identification, hit finding, lead optimization, and preclinical development into a coordinated workflow for partners. Through this platform, Evotec can support pharmaceutical and biotech clients in progressing candidate molecules from early discovery stages toward clinical readiness, potentially reducing timelines and development risk.

These services typically combine high-throughput screening, structure-based design, and in vitro and in vivo pharmacology, allowing partners to outsource significant parts of the discovery chain while maintaining strategic control over key assets. The platform generates recurring research revenues and creates opportunities for milestone and royalty streams when partnered projects advance successfully.

Evotec stock pricing snapshot

Evotec AG O.N. shares on the Frankfurt Stock Exchange closed at EUR 3.25 as of August 31, 2026 in late trade, with the stock down 3.05 percent on the session and marked as having fallen to a five-year low at that price level. The late-trade summary provides this closing value and contextualizes Evotec as one of the weakest names in the German market on that day.

Fact box

Company: Evotec SE

ISIN: DE0005664809

Ticker: EVTG

Exchange: Frankfurt Stock Exchange (Xetra)

Price (as of August 31, 2026, late trade): EUR 3.25

Sector / Industry: Biotechnology / Drug discovery services

Index membership: MDAX (Germany mid-cap index)